March 2025

UT Southwestern Microbiology Department Seminar 2025: Resurrecting Dr. Edward Jenner’s 1796 Horsepox Vaccine to Protect Against Mpox and Smallpox

March 2025

Controversies in Fibromyalgia 2025: Transmucosal Sublingual Cyclobenzaprine (TNX-102 SL) Treatment of Fibromyalgia at Bedtime to Target Non-Restorative Sleep Showed Durable Pain Reduction in Two Double-Blind Randomized Phase 3 Studies

November 2024

American College of Pheumatology Convergence 2024: Randomized, Double-Blind, Placebo-Controlled Confirmatory Phase 3 Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Fibromyalgia

October 2024

World Vaccine Congress: TNX-801 MPOX — A live, attenuated, minimally replicative, MPOX vaccine candidate

September 2024

Pharmaceutics and Novel Drug Delivery Systems (PDDS) Conference 2024: The Importance of in Vitro Discriminatory Tests in the Development of a Sublingual Dosage Form of TNX-102 SL (Cyclobenzaprine HCI) Tablets

September 2024

Pharmaceutics and Novel Drug Delivery Systems (PDDS) Conference 2024: Pharmacokinetic Properties of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine Hydrochloride

September 2024

Symposium to Honor Prof. David Evans: Using Synthetic Biology to Battle Mpox

August 2024

MHSRS 2024: Integrating Automated High-Throughput Scratch Assay and Cell Painting for Comprehensive Analysis of Cell Migration and Wound Healing

August 2024

MHSRS 2024: Two Clinical Trials of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Military-Related Posttraumatic Stress Disorder (PTSD) Provide Rationale to Study TNX-102 SL in the Aftermath of Trauma to Reduce Acute Stress Disorder (ASD) and Prevent PTSD

August 2024

MHSRS 2024: Development of the AURORA Platform Trial Network to Test Interventions to Reduce Acute Stress Reaction Symptoms, and Illustration of Use Testing Sublingual Cyclobenzaprine TNX-102 SL